Health
STAT+: Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
Publication: STAT
Author: Adam Feuerstein
Source published: 17/11/2026, 12:00:00 UTC
Briefing created: 17/11/2026, 13:58:25 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 13:51:25 UTC.
Briefings
A clinical trial involving Sellas Life Sciences' experimental blood cancer immunotherapy, galinpepimut-S, reported a 41% reduction in death risk for patients with advanced acute myeloid leukemia (AML). This outcome met the primary goal of the Phase 3 study, leading to a reversal of a previous prediction that the therapy would fail to prolong survival.
Key points
- The Phase 3 clinical trial for galinpepimut-S in patients with advanced acute myeloid leukemia (AML) achieved its main goal by reducing the risk of death by 41% compared to standard treatment.
- The therapy was previously predicted to fail in the Phase 3 study, but the new data indicates it successfully prolonged survival in the trial cohort.
Context
This finding represents a significant shift in the evaluation of Sellas Life Sciences' experimental blood cancer immunotherapy, reversing a prior negative prediction and suggesting potential efficacy for advanced AML patients.
Limitations
The evidence is limited to a single Phase 3 clinical trial with a specific outcome; no additional data on long-term survival, patient demographics, or broader clinical application is provided.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 17/11/2026, 13:58:25 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeicopdqv27np72rmtr77x6tvjvku7gdduxfkkowplch6f4rashcqoq